Wednesday, July 25th, 2007...5:15 am
Cleveland BioLabs to Present Protectan CBLB502 at 2007 BARDA Industry Day (Marketwire via Yahoo! Finance)
Jump to Comments
Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Mitigation Of Hematopoietic Damage at 48 Hours Post-Exposure … (Marketwire via Yahoo! Finance) Cleveland BioLabs Founding Partner Cleveland Clinic Receives Department of Defense Grant to Study Protectans CBLB502 … (Marketwire via Yahoo! Finance) Cleveland BioLabs Protectan CBLB502 Demonstrates Significant Reduction of Adverse Effects of Chemotherapeutic Drug in … (Marketwire via Yahoo! Finance) Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Mitigation Of Hematopoietic Damage At 48 Hours Post-Exposure … (Medical News Today) Cleveland BioLabs Achieves Recovery From Neutropenia and Thrombocytopenia in Primates 48 Hours Post-Irradiation With … (Marketwire via Yahoo! Finance)
Cleveland BioLabs, Inc. today announced that it will present its Protectan CBLB502 at the 2007 Biomedical Advanced Research and Development Authority Industry Day, on August 3, in Washington, DC.
Full story at cleveland-akron news
Share your Opinion